Detail akcie Cormedix Rg online

Business Summary: CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CorMedix Inc revenues increased from $12.3M to $183.1M. Net income totaled $149M vs. loss of $31.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest income increase of 43% to $3M (income), Interest Expenses decrease of 37% to $17K (expense).